Background: Small nucleolar RNA host gene (SNHG ) family members are newly recognized lncRNAs, which have been revealed to be oncogenes in several cancers. However, little studies investigated the expression and clinical implications of SNHGs  in AML.
Methods: Herein, we systemically determined the prognostic role of the expression of SNHG  family members in acute myeloid leukemia (AML).
Results: Among the expression of all SNHG  family members, we identified that only SNHG7  and SNHG12  expression were found to have prognostic effects on overall survival (OS) and leukemia-free survival (LFS) in AML by Cox regression univariate analysis. Furthermore, Kaplan–Meier analysis showed that SNHG7  higher-expressed cases had markedly longer OS and LFS time than SNHG7  lower-expressed cases, whereas SNHG12  higher-expressed cases had markedly shorter OS and LFS time than SNHG12  lower-expressed cases. Interestingly, SNHG7  and SNHG12  expression were also associated with several prognosis-related clinical/molecular features such as white blood cell counts, FAB/cytogenetic classifications, IDH1  mutation, RUNX1  mutation, and NPM1  mutation. Despite the associations, Cox regression multivariate analysis confirmed the independent prognostic impact of SNHG7  and SNHG12  expression in AML. Notably, we further validated that both SNHG7  and SNHG12  expression was significantly increased in newly diagnosed AML patients.
Conclusion: Our findings demonstrated that SNHG7  and SNHG12  expression act as independent prognostic indicators in AML.
Keywords: LncRNA, SNHG , expression, prognosis, AML